Prognostic value of visual IMPeTUs criteria and metabolic tumor burden at baseline [
FDG
Imaging
MTV
Myeloma
PET
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
28 May 2024
28 May 2024
Historique:
received:
05
04
2024
accepted:
22
05
2024
medline:
29
5
2024
pubmed:
29
5
2024
entrez:
28
5
2024
Statut:
epublish
Résumé
2-[ Patients with MM who underwent a baseline [ A total of 40 patients with NDMM were included in the study. The observers agreement in the analysis [18F]FDG PET/CT images was substantial for the presence of spine FL, extra spine FL, at least one fracture and paramedullary disease (Cohen's kappa 0.79, 0.87, 0.75 and 0.64, respectively). For the presence of skull FL and extramedullary disease the agreement was moderate (Cohen's kappa 0.56 and 0.53, respectively). Among [ Our work confirms the reproducibility IMPeTUs criteria. Furthermore, it demonstrates that a high number of FL (n > 10; IMPeTUs F group 4), reflecting a high [
Sections du résumé
BACKGROUND
BACKGROUND
2-[
METHODS
METHODS
Patients with MM who underwent a baseline [
RESULTS
RESULTS
A total of 40 patients with NDMM were included in the study. The observers agreement in the analysis [18F]FDG PET/CT images was substantial for the presence of spine FL, extra spine FL, at least one fracture and paramedullary disease (Cohen's kappa 0.79, 0.87, 0.75 and 0.64, respectively). For the presence of skull FL and extramedullary disease the agreement was moderate (Cohen's kappa 0.56 and 0.53, respectively). Among [
CONCLUSION
CONCLUSIONS
Our work confirms the reproducibility IMPeTUs criteria. Furthermore, it demonstrates that a high number of FL (n > 10; IMPeTUs F group 4), reflecting a high [
Identifiants
pubmed: 38806885
doi: 10.1186/s13550-024-01113-6
pii: 10.1186/s13550-024-01113-6
doi:
Types de publication
Journal Article
Langues
eng
Pagination
51Informations de copyright
© 2024. The Author(s).
Références
Ludwig H, Novis Durie S, Meckl A, Hinke A, Durie B. Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. Oncologist. 2020;25(9):e1406–13.
pubmed: 32335971
pmcid: 7485361
doi: 10.1634/theoncologist.2020-0141
van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410–27.
pubmed: 33516340
doi: 10.1016/S0140-6736(21)00135-5
Tacchetti P, Pantani L, Patriarca F, Petrucci MT, Zamagni E, Dozza L, et al. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Lancet Haematol. 2020;7(12):e861–73.
pubmed: 33242443
doi: 10.1016/S2352-3026(20)30323-9
Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395(10218):132–41.
pubmed: 31836199
doi: 10.1016/S0140-6736(19)32956-3
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–9.
pubmed: 26240224
pmcid: 4846284
doi: 10.1200/JCO.2015.61.2267
D’Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European myeloma network (EMN) report within the harmony project. J Clin Oncol. 2022;40(29):3406–18.
pubmed: 35605179
doi: 10.1200/JCO.21.02614
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46.
pubmed: 27511158
doi: 10.1016/S1470-2045(16)30206-6
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.
pubmed: 25439696
doi: 10.1016/S1470-2045(14)70442-5
Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):e206–17.
pubmed: 28368259
doi: 10.1016/S1470-2045(17)30189-4
Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20(6):e302–12.
pubmed: 31162104
doi: 10.1016/S1470-2045(19)30309-2
Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017;8(1):268.
pubmed: 28814763
pmcid: 5559527
doi: 10.1038/s41467-017-00296-y
Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989–95.
pubmed: 21900189
doi: 10.1182/blood-2011-06-361386
Li J, Zhang X, Qin C, Sun X, Xu X, Cao G, et al. A prognostication system based on clinical parameters and [(18)F]-FDG PET/CT in patients with newly diagnosed multiple myeloma. Eur J Nucl Med Mol Imaging. 2023;50(6):1665–70.
pubmed: 36576511
doi: 10.1007/s00259-022-06088-x
Kraeber-Bodere F, Zweegman S, Perrot A, Hulin C, Caillot D, Facon T, et al. Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study. Haematologica. 2023;108(2):621–6.
pubmed: 36263839
doi: 10.3324/haematol.2021.280051
Sachpekidis C, Merz M, Raab MS, Bertsch U, Weru V, Kopp-Schneider A, et al. The prognostic significance of [(18)F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs). EJNMMI Res. 2021;11(1):100.
pubmed: 34628525
pmcid: 8502185
doi: 10.1186/s13550-021-00846-y
Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, et al. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel IMPeTUs (Italian Myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2016;43(3):414–21.
pubmed: 26475305
doi: 10.1007/s00259-015-3200-9
Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, et al. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2018;45(5):712–9.
pubmed: 29270787
doi: 10.1007/s00259-017-3909-8
Nanni C. PET-FDG: impetus. Cancers Basel. 2020;12(4):1030.
pubmed: 32331374
pmcid: 7226158
doi: 10.3390/cancers12041030
Deng S, Zhang B, Zhou Y, Xu X, Li J, Sang S, et al. The role of (18)F-FDG PET/CT in multiple myeloma staging according to IMPeTUs: comparison of the durie-salmon plus and other staging systems. Contrast Media Mol Imaging. 2018;2018:4198673.
pubmed: 30154686
pmcid: 6091330
doi: 10.1155/2018/4198673
Sachpekidis C, Enqvist O, Ulen J, Kopp-Schneider A, Pan L, Mai EK, et al. Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [(18)F]FDG PET/CT predicts survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2024. https://doi.org/10.1007/s00259-024-06668-z .
doi: 10.1007/s00259-024-06668-z
pubmed: 38456971
Alberge JB, Kraeber-Bodere F, Jamet B, Touzeau C, Caillon H, Wuilleme S, et al. Molecular signature of (18)F-FDG PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study. J Nucl Med. 2022;63(7):1008–13.
pubmed: 35086897
pmcid: 9258580
doi: 10.2967/jnumed.121.262884
Fonti R, Larobina M, Del Vecchio S, De Luca S, Fabbricini R, Catalano L, et al. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med. 2012;53(12):1829–35.
pubmed: 23071351
doi: 10.2967/jnumed.112.106500
McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, et al. Assessment of total lesion glycolysis by (18)F FDG PET/CT significantly improves prognostic value of GEP and ISS in myeloma. Clin Cancer Res. 2017;23(8):1981–7.
pubmed: 27698001
doi: 10.1158/1078-0432.CCR-16-0235
Terao T, Machida Y, Tsushima T, Miura D, Narita K, Kitadate A, et al. Pre-treatment metabolic tumour volume and total lesion glycolysis are superior to conventional positron-emission tomography/computed tomography variables for outcome prediction in patients with newly diagnosed multiple myeloma in clinical practice. Br J Haematol. 2020;191(2):223–30.
pubmed: 32253760
doi: 10.1111/bjh.16633
Fonti R, Pellegrino S, Catalano L, Pane F, Del Vecchio S, Pace L. Visual and volumetric parameters by 18F-FDG-PET/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma. Ann Hematol. 2020;99(1):127–35.
pubmed: 31776725
doi: 10.1007/s00277-019-03852-2
Wan B, Zhang S, Wang P, Deng P, Dai W. Prognostic value of semi-quantitative parameters of (18)F-FDG PET/CT in newly diagnosed multiple myeloma patients. Ann Nucl Med. 2023;37(3):155–65.
pubmed: 36528697
doi: 10.1007/s12149-022-01812-x
Lee H, Hyun SH, Cho YS, Moon SH, Choi JY, Kim K, et al. Cluster analysis of autoencoder-extracted FDG PET/CT features identifies multiple myeloma patients with poor prognosis. Sci Rep. 2023;13(1):7881.
pubmed: 37188831
pmcid: 10185699
doi: 10.1038/s41598-023-34653-3
Terao T, Machida Y, Narita K, Kuzume A, Tabata R, Tsushima T, et al. Total diffusion volume in MRI vs. total lesion glycolysis in PET/CT for tumor volume evaluation of multiple myeloma. Eur Radiol. 2021;31(8):6136–44.
pubmed: 33496828
doi: 10.1007/s00330-021-07687-2
Jamet B, Morvan L, Nanni C, Michaud AV, Bailly C, Chauvie S, et al. Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. Eur J Nucl Med Mol Imaging. 2021;48(4):1005–15.
pubmed: 33006656
doi: 10.1007/s00259-020-05049-6
Khodarahmi I, Alizai H, Chalian M, Alaia EF, Burke CJ, Slasky SE, et al. Imaging spectrum of calvarial abnormalities. Radiographics. 2021;41(4):1144–63.
pubmed: 34197249
doi: 10.1148/rg.2021200198
Caers J, Withofs N, Hillengass J, Simoni P, Zamagni E, Hustinx R, et al. The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. Haematologica. 2014;99(4):629–37.
pubmed: 24688111
pmcid: 3971072
doi: 10.3324/haematol.2013.091918
Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, et al. Standardization of (18)F-FDG-PET/CT according to deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. J Clin Oncol. 2021;39(2):116–25.
pubmed: 33151787
doi: 10.1200/JCO.20.00386
Rasche L, Schinke C, Maura F, Bauer MA, Ashby C, Deshpande S, et al. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nat Commun. 2022;13(1):4517.
pubmed: 35922426
pmcid: 9349320
doi: 10.1038/s41467-022-32145-y
Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(7):719–34.
pubmed: 27291302
pmcid: 5291298
doi: 10.1002/ajh.24402
Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, et al. Prospective evaluation of magnetic resonance imaging and [(18)F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 Trial: results of the IMAJEM study. J Clin Oncol. 2017;35(25):2911–8.
pubmed: 28686535
pmcid: 5578392
doi: 10.1200/JCO.2017.72.2975
Michaud-Robert AV, Zamagni E, Carlier T, Bailly C, Jamet B, Touzeau C, et al. Glucose metabolism quantified by SUVmax on baseline FDG-PET/CT predicts survival in newly diagnosed multiple myeloma patients: combined harmonized analysis of two prospective phase III trials. Cancers (Basel). 2020;12(9):2532.
pubmed: 32899991
doi: 10.3390/cancers12092532
Morales-Lozano MI, Viering O, Samnick S, Rodriguez-Otero P, Buck AK, Marcos-Jubilar M, et al. (18)F-FDG and (11)C-Methionine PET/CT in newly diagnosed multiple myeloma patients: comparison of volume-based PET biomarkers. Cancers (Basel). 2020;12(4):1042.
pubmed: 32340251
pmcid: 7226577
doi: 10.3390/cancers12041042
Barrington SF, Zwezerijnen B, de Vet HCW, Heymans MW, Mikhaeel NG, Burggraaff CN, et al. Automated segmentation of baseline metabolic total tumor burden in diffuse large B-cell lymphoma: which method is most successful? A study on behalf of the PETRA consortium. J Nucl Med. 2021;62(3):332–7.
pubmed: 32680929
pmcid: 8049348
doi: 10.2967/jnumed.119.238923
Rasche L, Alapat D, Kumar M, Gershner G, McDonald J, Wardell CP, et al. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia. 2019;33(7):1713–22.
pubmed: 30573775
doi: 10.1038/s41375-018-0329-0
Terao T, Machida Y, Hirata K, Kuzume A, Tabata R, Tsushima T, et al. Prognostic impact of metabolic heterogeneity in patients with newly diagnosed multiple myeloma using 18F-FDG PET/CT. Clin Nucl Med. 2021;46(10):790–6.
pubmed: 34172600
doi: 10.1097/RLU.0000000000003773
Sachpekidis C, Enqvist O, Ulen J, Kopp-Schneider A, Pan L, Jauch A, et al. Application of an artificial intelligence-based tool in [(18)F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma. Eur J Nucl Med Mol Imaging. 2023;50(12):3697–708.
pubmed: 37493665
pmcid: 10547616
doi: 10.1007/s00259-023-06339-5
Takahashi MES, Mosci C, Souza EM, Brunetto SQ, Etchebehere E, Santos AO, et al. Proposal for a quantitative (18)F-FDG PET/CT metabolic parameter to assess the intensity of bone involvement in multiple myeloma. Sci Rep. 2019;9(1):16429.
pubmed: 31712729
pmcid: 6848137
doi: 10.1038/s41598-019-52740-2
Paschali A, Panagiotidis E, Triantafyllou T, Palaska V, Tsirou K, Verrou E, et al. A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy. Eur J Nucl Med Mol Imaging. 2021;48(5):1487–97.
pubmed: 33099659
doi: 10.1007/s00259-020-05078-1